Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

96-week comparative study of Clevudine versus Viread(R) versus

Clevudine+Viread(R) in 150 patients with chronic hepatitis B

PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc. (Nasdaq: VRUS) and Gilead Sciences, Inc. (Nasdaq: GILD), has initiated the first head-to-head study of clevudine and Viread(R) (tenofovir disoproxil fumarate) administered separately, versus their combination, for the treatment of chronic hepatitis B virus (HBV) infection in non-cirrhotic patients. The study treatments include clevudine 30mg/day, tenofovir 300mg/day or the combination of both drugs administered to 150 treatment-naive hepatitis B e-antigen negative HBV-infected patients for 96 weeks. At that time, all therapy will be discontinued, and patients will be monitored for sustained virologic response (SVR) after being off of therapy for 24 weeks, the primary endpoint of the study.

Clevudine is an oral, once-daily pyrimidine nucleoside analog that has been evaluated in 18 clinical trials in more than 800 individuals. Phase 3 studies are currently being conducted in approximately 140 global clinical sites to support the registration of clevudine in the Americas and Europe. Pharmasset licensed clevudine for these territories from Bukwang Pharm. Co., Ltd, who has received South Korean regulatory approval and is currently marketing clevudine in South Korea under the brand name Levovir.

"Clevudine's
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... N.J. , March 26, 2015 IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... of ANDA submissions now pending at the FDA to ... CEO of the Company, commented, "On March 2, 2015, ...
(Date:3/26/2015)...  CNBC profiled MJ Freeway , a business software ... "How I Did It," which features companies with unique paths ... released yesterday, illustrates how two tech entrepreneurs from ... the marijuana industry. ... Poinsett and Jessica Billingsley used their experience in ...
(Date:3/26/2015)... 26, 2015 Editor Note: ... bottom . Investor-Edge has initiated coverage on ... Salix Pharmaceuticals Ltd (NASDAQ: SLXP ), Hospira Inc. ... ), and Akorn Inc. (NASDAQ: AKRX ). Free ... http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL . The US markets declined on Wednesday, March ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 3Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 4Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 5
... LITTLE FALLS, N.J., Feb. 2, 2011 Projects ... provider of continuing medical education (CME/CE) activities, previously ... game-changing Living Medical eTextbook. Now the iPhone app ... recognized by iMedicalApps ( www.imedicalapps.com ) as one ...
... and PRINCETON, N.J., Feb. 2, 2011 Eli Lilly ... Squibb Company (NYSE: BMY ) announced today ... two global Phase III studies evaluating necitumumab, an investigational ... cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
Cached Medicine Technology:Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10
(Date:3/27/2015)... Airy Jeanine is a rising star. ... video for her debut song “Mama’s Girl”, launched on ... abstract styling effects, the thematic video for the rhythmic ... and assorted outlets. It will be integral in establishing, ... full-scale marketing strategy. The video promotion campaign spearheaded by ...
(Date:3/27/2015)... 27, 2015 “ VXi BlueParott Reveal ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... noise-cancelling headset, eliminating 90% of ambient noise. , Today, ... and emails are important to any professional, voice calls ...
(Date:3/27/2015)... March 27, 2015 The ... Quaker-based, philanthropic, grant-making foundation committed to raising its ... healthcare is delivered. , The Scattergood Foundation and ... Behavioral Health Policy and Practice through the Annual ... Program App is designed to guide the ...
(Date:3/26/2015)... Dr. Rod J. Rohrich, who served as ... and has trained over 6500 surgeons through these meetings ... medicine (EBM), that is, the optimization of decision making ... often hear from rhinoplasty surgeons who describe ... not trying to stifle these discussions, we do want ...
(Date:3/26/2015)... The American College of Traditional Chinese Medicine ... of the DAOM Program as well as Marketing Basics for ... be hosted by Dr. Carla Wilson, who will give an ... how to prepare for the spring quarter. The webinar will ... April 1 and April 3. Attendees can log in from ...
Breaking Medicine News(10 mins):Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:ACTCM Announces Upcoming Webinars 2
... seen with DHA, either in terms of prevention or ... Two trials that looked at whether the omega-3 fatty ... produced mixed results. , The studies were done because ... fish consumption to cognitive function," explained Bill Thies, chief ...
... A ... Meeting in Keystone, Colorado, (July 9-12) details the benefits and risks of repairing a torn ... ... More and more children are participating and getting hurt playing sports each year. A new ...
... , , NEW YORK ... Sub-Saharan Africa as president, Barack Obama today gave an historic speech ... address the deadly public health voids in many African countries, the ... mothers, noting "...too many still die from diseases that shouldn,t kill ...
... Mayo Clinic study may help physicians differentially ... study will be presented at the Alzheimer,s Association International ... , In this study, Mayo Clinic researchers developed ... neurodegenerative disorders: Alzheimer,s disease , frontotemporal lobar ...
... ... will join three other North American physicians as a 2009 American Orthopaedic Society ... ... John Bergfeld, MD, Cleveland Clinic Foundation, Director of Operating Room Management, will join three ...
... The Council for American Medical Innovation today applauded President ... head the National Institutes of Health (NIH). , ... ) , , "Dr. Collins is both a ... medical innovation," said Council President Dick Gephardt. "His passion ...
Cached Medicine News:Health News:Omega-3 Fatty Acid Falls Short in Alzheimer's Trials 2Health News:Omega-3 Fatty Acid Falls Short in Alzheimer's Trials 3Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 2Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 3Health News:Obama: 'Too Many Still Die from Diseases That Shouldn't Kill Them...' 2Health News:Mayo Clinic study using structural MRI may help accurately diagnose dementia patients 2Health News:Renowned, Cleveland Clinic Foundation, Orthopaedic Sports Medicine Surgeon, John Bergfeld, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Council for American Medical Innovation Applauds Appointment of Geneticist Francis Collins to Head National Institutes of Health 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: